中国医学科学院药物研究所-九游官网下载

刘艾林，女，博士，研究员，博士生导师，pi。1995年至今在中国医学科学院药物研究所工作。1998年-2000年参与筹建了国家药物筛选中心。2004年至今一直参与国家人口与健康科学数据共享平台建设工作。2018年-2019年在美国purdue university访问学习。主要从事防治神经退行性疾病新药、抗感染新药的发现与机制研究，以及计算药理学，网络药理学和药物信息学研究。
兼任世界中医药学会联合会网络药理学专业委员会常务理事，中国民族医药学会药理与毒理学分会理事，中国药理学会网络药理学专业委员会常务理事，北京精神神经药理专业委员会委员，国内外若干核心期刊审稿专家，项目评审专家等社会职务。

1、防治神经退行性疾病新药发现与机制研究
2、抗感染新药发现与机制研究
3、计算药理学，网络药理学，药物信息学

1、ailin liu*#, jun zhao#, nicholas j. huls, matthias zeller, lin wang, tonglei li*. the structural basis of dl0410, a novel multi-target candidate drug for the treatment of alzheimer’s disease. crystals 2024, 14(1), 59. https://doi.org/10.3390/cryst14010059.
2、xu l#, cai c#, fang j, wu q, zhao j, wang z, guo p, zheng l*, liu a*. systems pharmacology dissection of pharmacological mechanisms of xiaochaihu decoction against human coronavirus. bmc complement med ther. 2023 jul 20;23(1):252. doi: 10.1186/s12906-023-04024-6.
3、zhao j, xu l, bai y, wang c, guo p, wang z, du g, liu a*. the efficacy and mechanism of salmeterol against influenza a virus in vitro and in vivo. int immunopharmacol. 2023 jun;119:110226. doi: 10.1016/j.intimp.2023.110226.
4、jun zhao, qinhai ma, baoyue zhang, pengfei guo, zhe wang, yi liu, minsi meng, ailin liu*, zifeng yang*, and guanhua du*. exploration of sars-cov‑2 3clpro inhibitors by virtual screening methods, fret detection, and cpe assay. journal of chemical information and modeling, 2021 dec 27;61(12):5763-5773. https://doi.org/10.1021/acs.jcim.1c01089
5、cai c, xu l, fang j, dai z, wu q, liu x, wang q, fang j*, liu al*, du gh*. in silico prediction and bioactivity evaluation of chemical ingredients against influenza a virus from isatis tinctoria l. front pharmacol. 2021 dec 7;12:755396. doi: 10.3389/fphar.2021.755396.
6、mengwu xiao#, lvjie xu#, ding lin, wenwen lian, manying cui, meng zhang, xiaowei yan, shuishi li, jun zhao, jiao ye, ailin liu*, aixi hu*. design, synthesis, and bioassay of 4-thiazolinone derivatives as influenza neuraminidase inhibitors[j]. european journal of medicinal chemistry. 2021 mar 5;213:113161.
7. xu l#, jiang w#, jia h, zheng l, xing j, liu a*, du g*. discovery of multitarget-directed ligands against influenza a virus from compound yizhihao through a predictive system for compound-protein interactions. front cell infect microbiol. 2020 feb 11;10:16. doi: 10.3389/fcimb.2020.00016.
8、chen a, liang y, ye j, hu a*, lian w, liu a*, du g. synthesis of chalcone derivatives containing furan or/and pyran ring as neuraminidase inhibitors. chem res chinese universities, 2019, 35(3):395-402.
9、li c, xu lj, lian ww, pang xc, jia h, liu al*, du gh*. anti-influenza effect and action mechanisms of the chemical constituent gallocatechin-7-gallate from pithecellobium clypearia benth. acta pharmacol sin. 2018, 39(12):1913-1922.
10、liu j*#, zu m#, chen k, gao l, min h, zhuo w, chen w, liu a*. screening of neuraminidase inhibitory activities of some medicinal plants traditionally used in lingnan chinese medicines. bmc complement altern med. 2018, 18(1):102. doi: 10.1186/s12906-018-2173-1.
11、liu j*, zu m, chen k, gao l, min h, zhou w, chen w, and liu a*. screening of neuraminidase inhibitory activities of some medicinal plants traditionally used in lingnan chinese medicines. bmc complementary and alternative medicine, 2018, 18:102. https://doi.org/10.1186/ s12906-018-2173-1.
12、li c, song x, song j, pang x, wang z, zhang y, lian w, liu a*, du g*. pharmacokinetic study of gallocatechin-7-gallate from pithecellobiumclypearia benth. in rats. acta pharmaceutica sinica b, 2016, 6(1): 64-70.
13、 zu m#, li c#, fang js, lian ww, liu al*, zheng ls*, du gh*. drug discovery of host clk1 inhibitors for influenza treatment. molecules, 2015, 20, 19735–19747.
14、zhang b, zhao j, wang z, guo p, liu a* and du g*. identification of multi-target anti-adchemical constituents from traditional chinese medicine formulae by integrating virtual screening and in vitro validation. front. pharmacol., 2021, 12:709607. doi: 10.3389/fphar.2021.709607.
15、 zhou w, lian ww, yan r, jia h, xu lj, wang l, liu al*, du gh*. dl0410 ameliorates cognitive deficits in app/ps1 transgenic mice by promoting synaptic transmission and reducing neuronal loss. acta pharmacol sin. 2020, 41(5):599-611.
16、lian ww, zhou w, zhang by, jia h, xu lj, liu al*, du gh*. dl0410 ameliorates cognitive disorder in samp8 mice by promoting mitochondrial dynamics and the nmdar-creb-bdnf pathway. acta pharmacol sin. 2020 aug 31. doi:10.1038/s41401-020-00506-2.
17、zhang b, zhao j, wang z, xu l, liu a*, du g*. dl0410 attenuates oxidative stress and neuroinflammation via bdnf/trkb/erk/creb and nrf2/ho-1 activation. int immunopharmacol. 2020 jul 6;86:106729. doi: 10.1016/j.intimp.2020.106729.
18、 pang x#, zhang b#, mu g, xia j, xiang q, zhao x, liu a*, du g*, cui y*. screening of cytochrome p450 3a4 inhibitors via in silico and in vitro approaches. rsc adv, 2018, 8, 34783-34792.
19、 pang x, zhao y, song j, kang, wu s, wang l, liu a*, du g*. pharmacokinetics, excretion and metabolites analysis of dl0410, a dual acting cholinesterase inhibitor and histamine 3 receptor antagonist. mol med rep. 2019, 20: 1103-1112.
20、pang x, fu w, wang j, kang d, xu l, zhao y, liu al*, du gh*. identification of estrogen receptor α antagonists from natural products by virtual screening approaches. oxid med cell longev. 2018, 2018: 6040149. doi:10.1155/2018/6040149.
21、pang xc, kang d, fang js, zhao y, xu vj, lian ww, liu al*, du gh*. network pharmacology-based analysis of chinese herbal naodesheng formula for application to alzheimer’s disease. chinese journal of natural medicines, 2018, 16(1): 0053-0062.
22、 lian w, fang j, xu l, zhou w, kang d, xiong w, jia h, liu al*, du gh*. dl0410 ameliorates memory and cognitive impairments induced by scopolamine via increasing cholinergic neurotransmission in mice. molecules. 2017, 22(3), 410. pii: e410.
23、lian w, jia h, xu l, zhou w, kang d, liu a*, du g*. multi-protection of dl0410 in ameliorating cognitive defects in d-galactose induced aging mice. front aging neurosci. 2017, 9:409. doi: 10.3389/fnagi.2017.00409.
24、 fang j, wang l, li y, lian w, pang x, wang h, yuan d, wang q*, liu al*, du gh*. alzhcpi: a knowledge base for predicting chemical-protein interactions towards alzheimer's disease. plos one. 2017 may 25;12(5):e0178347. doi: 10.1371/journal.pone.0178347. ecollection 2017.
25、pang x, zhao y, wang j, li w, xiang q, zhang z, wu s, liu al*, cui ym* and du gh*. competing endogenous rna and co-expression network analysis for identification of potential biomarkers and therapeutics in association with metastasis risk and progression of prostate cancer. oxid med cell longev. 2019, 2019:8265958.
26、zhang by, zheng yf, pang xc, wang z, ding h, liu al*. network pharmacology based study of the active constituents of chinese medicinal formulae for antitumor mechanism. world j tradit chin med, 2018, 4(2):43-53.
27、 kang d, pang x, lian w, xu l, wang,j, jia h, zhang b, liu al*, du gh*. discovery of vegfr2 inhibitors by integrating naıve bayesian classification, molecular docking and drug screening approaches. rsc advances, 2018, 8: 5286- 5297.

1、《实验药理学》（第二版）。编者，北京：高等教育出版社，2020年。
2、《迈向药物创新之路—“1035工程”实施回顾》。编者，北京：高等教育出版社，2019年。
3、《中药材“毒”古今研究概评》。编委，北京：中国医药科技出出版社，2019年。
4、《天然小分子药物》。编委，北京：人民卫生出版社，2018年。
5、 natural small molecule drugs from plants. springer, 2018.
6、 dietary phytochemicals and microbes. compiled chapter 3 (pp33-126). springer sciences, business media dordrecht, 2012.

1. 刘艾林，谭文杰，郑丽舒，许律捷，赵君，吴松，康洁，张文轩，叶飞，郭鹏飞，李超，贾皓，杜冠华。没食子儿茶素-7-没食子酸酯在抗冠状病毒药物中的用途。申请日期：2021年3月15日，申请号：202110276445.2。
2. 刘艾林，吴松，杜冠华，王冬梅，方坚松，周围，连雯雯，庞晓丛。金雀异黄酮衍生物在多靶点改善学习记忆障碍中的作途，申请日期：2016年12月26日，申请号：2016112071083
3. 杜冠华，吴松，刘艾林，周丹，王冬梅，冯章英，李莉，刘前，一个异黄酮衍生物的多靶点作用及其改善学习记忆用途，专利号：zl201310113150.9，授权日期：2019年1月1日。
4. 秦海林，方莲花，张志辉，刘艾林，邓安珺，袁天翊，于金倩，李志宏，杜冠华。黄连碱衍生物、其合成方法及其抗肿瘤的药物用途，专利号：zl201210411739.2，授权公告日：2016年09月14日。
5. 刘艾林，杜冠华，王琳，高梅，宫丽丽。对乙、丁酰胆碱酯酶具有双重抑制活性的化合物及其用途。专利号：zl 200710107604.6。

1. 2011 年，“天然产物的生物活性评价研究”获得中华医学科技奖，叁等奖，
主要完成人：杜冠华， 刘艾林，张天泰，王月华，张莉，方莲花，陈若云，秦海林。
2. 2009 年，“新型高通量药物筛选用蛋白质芯片技术的研究与应用” 获北京市科学技术奖，贰等奖。主要完成人：杜冠华，周勇，张天泰，高峰， 刘艾林，方莲花，张莉，胡娟娟，王月华，何国荣。
3. 2002年，“高通量药物筛选技术体系的研究与应用” 获北京市科学技术奖,贰等奖，主要完成人：杜冠华，王晓良，胡娟娟， 刘艾林，黄家学，尚念勇，孙缅恩，张莉，肖玉霞。
4. 2002 年，“高通量药物筛选技术体系的研究与应用”获中华医学科技奖，叁等奖。主要完成人：杜冠华，王晓良，胡娟娟， 刘艾林，黄家学，尚念勇，孙缅恩，张莉。
5. 2018 年，“天然产物成药性评价技术创新及应用”于 获得中华医学科技奖，叁等奖。主要完成人：杜冠华，王月华，方莲花，吕扬，张莉，杨秀颖， 刘艾林，王守宝。